Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 210

The DOI matches its Crossref record.

Use of Recombinant Human Bone Morphogenetic Protein-2 in Spinal Fusion Applications

McKay, Bill, Sandhu, Harvinder S. · 2002 · Spine

Abstract

Bone morphogenetic proteins (BMPs) have been the subject of considerable research for several decades. The academic chronicle began in 1965 with Dr. Marshall Urist’s discovery of osteoinductive activity within demineralized bone protein extracts, and continued with his later identification of the active molecules as bone morphogenetic proteins. 23,24 This was followed in 1988 by the isolation of an individual protein, BMP-2, from a purified extract and its recombinant production. 25 The long-awaited clinical use and commercial availability of BMPs have only recently approached reality. Recombinant human bone morphogenetic protein-2 (rhBMP-2) is the only BMP for which a prospective randomized pivotal clinical trial for a spine fusion indication has been completed. It has demonstrated equivalence to autogenous iliac bone graft with regard to both fusion rate and clinical outcome. 7 On the basis of this study, the Food and Drug Administration (FDA) has advised that rhBMP-2 be approved for commercialization as the first complete bone graft substitute for spinal fusion indication. At this writing, all other FDA-cleared bone-grafting products are only osteoconductive scaffolds incapable of solely initiating bone formation under the classic definition of osteoinduction: the ability to induce de novo bone formation at a nonbony site. A significant body of data on the use of rhBMP-2 in spinal fusion surgery has been collected. Both the potential uses of rhBMP-2 and its limitations in spinal fusion applications have become clear through this extensive series of preclinical and clinical investigations. It was determined that an application-specific carrier was required to release the rhBMP-2 protein over an adequate period and at a sufficient concentration. Different fusion techniques such as intervertebral arthrodesis and posterolateral intertransverse process arthrodesis presented their own specific challenges, which required specific carrier–rhBMP-2 combinations. The relevant preclinical and clinical research that provided data regarding site-specific product configurations is presented in this article. The first part of the article reviews some of the preclinical efficacy data and lessons learned from these animal studies. The second part describes FDA-approved investigational device exempted (IDE) clinical human trials and their results involving rhBMP-2 for human spinal fusions. Product Development Considerations Early work with rhBMP-2 demonstrated that the carrier had a profound effect on the efficacy of the molecule for specific applications. It was determined that the carrier serves three very important functions: It acts as a three-dimensional space occupier and scaffolding across which de novo bone formation can occur. It maintains a critical threshold concentration of BMP at the site of implantation for the desired period. It contains the BMP at the site of application to prevent extraneous bone formation. Several carriers for rhBMP-2 have been evaluated including collagen sponges, calcium phosphate ceramics, and degradable synthetic and natural polymers. Each of these vehicles offers its own unique advantages and disadvantages. The efficacy of the carrier–growth factor composite was evaluated largely through preclinical research, which requires a long iterative trial and error process. Ideally, a carrier is a resorbable material with a resorption profile that generally matches the rate of de novo bone formation. If the carrier resorbs before adequate osteodeposition, misdirected bone formation and pseudarthrosis may be the ultimate result. If the carrier resorbs too slowly, bridging bone formation and remodeling may be impeded. Preclinical research is complicated by the fact that rhBMP-2 efficacy is species dependent (i.e., higher concentrations of the molecule are required in more evolved animals). Thus, a valid determination of the efficacy of the carrier–rhBMP-2 composite, before initiation of human clinical trials, ultimately is dependent on findings in primate studies using clinically relevant models. Two of the more common spinal fusion procedures are interbody fusion using load-bearing cages and posterolateral intertransverse process fusion. Because these two distinct spine fusion techniques involve different mechanical and biologic demands, specific carrier–rhBMP-2 composite configurations were indicated for each technique. Therefore, preclinical findings with interbody and posterolateral fusion techniques were reviewed separately. Preclinical Studies by Site of Application Interbody Spinal Fusion The intention of interbody spinal fusion is to achieve a bony arthrodesis across a degenerated and usually narrowed disc space. In the process of achieving fusion, the intervertebral space is distracted to a reasonable approximation of its original height with the intent of restoring sagittal plane alignment. At the time of this writing, no carrier material could be identified that could deliver the mol

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00007632-200208151-00014

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 210

Metadata

Authors
McKay, B., & Sandhu, H. S.
Venue
Spine
Published
2002-08
Volume
27
Issue
Supplement
Pages
S66-S85
ISSN
0362-2436 (ISSN-L)
OpenAlex
W2088479826
Cited by
210
References
0
FWCI
8.14
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of Recombinant Human Bone Morphogenetic Protein-2 in Spinal Fusion Applications. https://app.cochat.ai/papers/10.1097/00007632-200208151-00014
The paper
McKay, B., & Sandhu, H. S. (2002). Use of Recombinant Human Bone Morphogenetic Protein-2 in Spinal Fusion Applications. Spine. https://doi.org/10.1097/00007632-200208151-00014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.